

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Michael C. Badia on 6-2-08.

The application has been amended as follows:

Claim 18: On page 10, the first line, delete the phrase "**according to claim 1**".

Allowable Subject Matter

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(c), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(c) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4-2-08 has been entered.

Claims 8 and 10-16 have been cancelled.

Claims 1-7, 9, 17 and 18 are pending.

The amended claims have overcome the previous rejections of 112/2nd paragraph, 102 and 103 based on Fujimori et. al. (EP'835 or US'928 cited previously).

Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance:

The invention is drawn to compounds of substituted dioxo-quinazoline and pharmaceutical composition thereof. By deleting hydrogen from the definition of R₁, and requiring "n" to be one, the instant claims have excluded the compounds disclosed by **Fujimori et. al.** No other references are found teaching or fairly suggested a dioxo-quinazoline compound with the combination of substituents represented by R₁-R₄ and R_a.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAMTHOM N. TRUONG whose telephone number is (571)272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1624

system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tamthom N. Truong/

/James O. Wilson/
Supervisory Patent Examiner, Art Unit 1624

Tamthom N. Truong
Examiner
Art Unit 1624

6-3-08